Januvia approved as add-on to insulin treatment

Januvia (sitagliptin) can now be prescribed as an add-on to insulin (with or without metformin) for patients with type II diabetes in whom diet and exercise, plus a stable dose of insulin, do not provide adequate glycaemic control. In a 24-week study in 305 patients, addition of sitagliptin to insulin significantly improved glycaemic parameters compared with placebo, with no major effect on body weight. When Januvia is combined with insulin, reduction of the insulin dose may be appropriate to reduce the risk of hypoglycaemia.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Januvia no longer contraindicated in renal impairment

Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases